Targeted Oncology : Impact Factor & More
eISSN: 1776-260XpISSN: 1776-2596
Share this on:
Key Metrics
CiteScore 
7.2
Impact Factor
5 - 10
SJR
Q2Oncology
SNIP
1.03
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Targeted Oncology
Targeted Oncology Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2006 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Targeted Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Targeted Oncology
Correction: Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.
- 30 Jun 2026
- Targeted oncology
Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.
- 29 Jun 2026
- Targeted oncology
Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis.
- 8 Jun 2026
- Targeted oncology
Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.
- 4 Jun 2026
- Targeted oncology
Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?
- 31 May 2026
- Targeted oncology
Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review.
- 30 May 2026
- Targeted oncology
Correction: Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.
- 30 Jun 2026
- Targeted oncology
Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.
- 29 Jun 2026
- Targeted oncology
Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis.
- 8 Jun 2026
- Targeted oncology
Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.
- 4 Jun 2026
- Targeted oncology
Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?
- 31 May 2026
- Targeted oncology
Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review.
- 30 May 2026
- Targeted oncology
FAQs on Targeted Oncology
How long has Targeted Oncology been actively publishing? 
What is the publishing frequency of Targeted Oncology?
How many articles did Targeted Oncology publish last year?
What is the eISSN & pISSN for Targeted Oncology?
What is Citescore for Targeted Oncology?
What is SNIP score for Targeted Oncology?
What is the SJR for Targeted Oncology?
Who is the publisher of Targeted Oncology?
